We integrate deep-rooted biological expertise, apply advanced single-cell profiling technologies and leverage open-innovation strategies to accelerate the development of a repertoire of innovative antibody drugs that will soon transform patient care.

Dynamic and Sustainable Pipeline

We are developing a robust pipeline of novel therapeutic antibodies that mobilize the human immune system to combat cancer and autoimmune disorders. With a sharp focus on regulatory T cells and Myeloid-derived suppressor cells, our programs aim to modulate multiple immune cell types and key pathways. Highlights of our pipeline include:

  • Majority are against first-in-class targets with new disease biology and proprietary biological insights
  • Our best-in-class programs against validated targets focus on differentiated characteristics or novel mechanisms of action
  • Multiple preclinical candidates have demonstrated proof of concept in animal models
  • We leverage strategic collaborations with top immunology/immuno-oncology experts in the world

Proven Single-Cell Platform

We apply our proprietary single-cell functional antibody screening CelliGO™ platform and unique single-cell immune profiling Drug Intelligent Science (DIS™) capabilities to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.

Key advantages of CelliGO include:

  • Ultra-high-throughput antibody selection with millions of B-cells analyzed per campaign
  • Unprecedented single-cell resolution and ability to differentiate hit diversity
  • Deep mining ability of the immune repertoire in a species agonistic manner
  • Enable to explore challenging targets such as multi-transmembrane proteins

Key advantages of DIS include:

  • Ability to examine the disease biology at the single-cell level
  • Novel algorithm leverages artificial intelligence for better drug design
  • Enhanced probability of success, especially for clinical trial design

Open-Innovation Partnerships

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand single-cell analytics and accelerate commercialization. All of our collaborations are architected for speed and driven by our scientific strategy.

Contact us today to learn more about our open-innovation strategies and partnerships

Recent Highlights

Research Collaboration


Antibody Discovery Agreement

Read our article in Drug Discovery Today for more information on our open-innovation strategy.

Publications and Posters

Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.

Scientific Publication

Nature Biotechnology

Nature Biotechnology: Single-cell deep phenotyping of lgG-secreting cells for high-resolution immune monitoring
Read More

Scientific Poster

Antibody Discovery by Deep Mining of Immune Repertoires

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Read More